Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Wasatch Advisors LP

Wasatch Advisors LP lessened its holdings in Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 52.5% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 9,231,505 shares of the biopharmaceutical company's stock after selling 10,210,863 shares during the period. Wasatch Advisors LP owned about 4.42% of Sangamo Therapeutics worth $9,416,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in SGMO. Golden State Equity Partners boosted its stake in shares of Sangamo Therapeutics by 2,592.3% during the 4th quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock worth $332,000 after acquiring an additional 313,587 shares during the last quarter. Geode Capital Management LLC grew its holdings in Sangamo Therapeutics by 14.6% during the third quarter. Geode Capital Management LLC now owns 2,138,309 shares of the biopharmaceutical company's stock valued at $1,853,000 after purchasing an additional 272,123 shares during the period. EAM Investors LLC purchased a new stake in Sangamo Therapeutics in the fourth quarter worth about $256,000. Virtu Financial LLC bought a new position in shares of Sangamo Therapeutics in the third quarter worth about $150,000. Finally, State Street Corp grew its stake in shares of Sangamo Therapeutics by 28.0% during the 3rd quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock valued at $576,000 after acquiring an additional 145,400 shares during the period. Hedge funds and other institutional investors own 56.93% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on SGMO. StockNews.com lowered shares of Sangamo Therapeutics from a "buy" rating to a "hold" rating in a research report on Tuesday, December 24th. Truist Financial decreased their target price on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating on the stock in a research note on Thursday, January 23rd. HC Wainwright reaffirmed a "buy" rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a report on Monday, April 7th. Royal Bank of Canada restated a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research report on Tuesday, March 18th. Finally, Jefferies Financial Group decreased their price target on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a research note on Tuesday, December 31st. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to MarketBeat.com, Sangamo Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $5.17.

Sangamo Therapeutics Stock Performance

SGMO stock traded up $0.01 during midday trading on Tuesday, reaching $0.75. 1,497,906 shares of the company traded hands, compared to its average volume of 8,440,936. The firm has a market capitalization of $168.08 million, a price-to-earnings ratio of -1.00 and a beta of 1.57. Sangamo Therapeutics, Inc. has a 52-week low of $0.30 and a 52-week high of $3.18. The business has a 50 day moving average of $0.87 and a 200-day moving average of $1.39.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The business had revenue of $7.55 million during the quarter, compared to analysts' expectations of $11.70 million. Research analysts anticipate that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.